Trial · NCT01549652
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
NCT01549652, Not applicable, Completed, Stanford University; results first posted 2019-01-07
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence. Trials, record NCT01549652. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01549652
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
- NCT number
- NCT01549652
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 133 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Opioid Withdrawal, Physical Dependence
- Interventions
- Ondansetron, Placebo, Morphine, Naloxone 0.4 mg/70 kg, Naloxone 0.8 mg/70 kg
- First posted
- 2012-03-09
- Last updated
- 2019-01-07
- Results first posted
- 2019-01-07
- Limitations and caveats
Aim 1: Use of a single 8mg dose of ondansetron as well as a lack of biochemical data is a limitation of this study.~Aim 2: Use of 8mg of ondansetron instead of varying doses is a limitation of this study.
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) | Baseline; 15 minutes following last naloxone dose | Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible. Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported. |
| Primary | Change in Objective Opioid Withdrawal Score From Baseline (Prevention of Physical Dependence) | Baseline; 15 minutes following last naloxone dose | Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal. Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported. |
| Secondary | Change in Subjective Opioid Withdrawal Score (SOWS) From Baseline (Prevention of Opioid Withdrawal) | Baseline; 15 minutes following last naloxone dose | The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported |
| Secondary | Beck Depression Inventory Score (BDIS) Change From Baseline (Prevention of Opioid Withdrawal) | 2 study days 1 month apart (at the start of each study visit) | The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). |
| Secondary | Profile of Mood States (POMS) Change in Score From Baseline (Prevention of Opioid Withdrawal) | Baseline; 15 minutes following last naloxone dose | Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. |
| Secondary | Change in Pain Visual Analog Scale (VAS) From Baseline (Prevention of Opioid Withdrawal) | 2 study days 1 month apart (at the start of each study visit) | The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). |
| Secondary | Change in Roland-Morris Disability Index (RMDI) From Baseline (Prevention of Opioid Withdrawal) | 2 study days 1 month apart (at the start of each study visit) | The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). |
| Secondary | Change in Subjective Opioid Withdrawal Score From Baseline (Prevention of Physical Dependence) | Baseline; 15 minutes following last naloxone dose | The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported |
| Secondary | Beck Depression Inventory Score (BDIS) Change From Baseline (Prevention of Physical Dependence) | 2 study days 1 month apart (at the start of each study visit) | The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). |
| Secondary | Profile of Mood States (POMS) Change in Score From Baseline (Prevention of Physical Dependence) | Baseline; 15 minutes following last naloxone dose | (Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) | Baseline; 15 minutes following last naloxone dose | Participants in the Prevention of Opioid Withdrawal Arm were analyzed. | units on a scale | MEAN |
| SECONDARY | Change in Subjective Opioid Withdrawal Score (SOWS) From Baseline (Prevention of Opioid Withdrawal) | Baseline; 15 minutes following last naloxone dose | Participants in the Prevention of Opioid Withdrawal Arm were analyzed. | units on a scale | MEAN |
| SECONDARY | Beck Depression Inventory Score (BDIS) Change From Baseline (Prevention of Opioid Withdrawal) | 2 study days 1 month apart (at the start of each study visit) | Participants in the Prevention of Opioid Withdrawal Arm were analyzed. | units on a scale | MEAN |
| SECONDARY | Profile of Mood States (POMS) Change in Score From Baseline (Prevention of Opioid Withdrawal) | Baseline; 15 minutes following last naloxone dose | Participants in the Prevention of Opioid Withdrawal Arm were analyzed. | units on a scale | MEAN |
| SECONDARY | Change in Pain Visual Analog Scale (VAS) From Baseline (Prevention of Opioid Withdrawal) | 2 study days 1 month apart (at the start of each study visit) | Participants in the Prevention of Opioid Withdrawal Arm were analyzed. | units on a scale | MEAN |
| SECONDARY | Change in Roland-Morris Disability Index (RMDI) From Baseline (Prevention of Opioid Withdrawal) | 2 study days 1 month apart (at the start of each study visit) | Participants in the Prevention of Opioid Withdrawal Arm were analyzed. | units on a scale | MEAN |
| PRIMARY | Change in Objective Opioid Withdrawal Score From Baseline (Prevention of Physical Dependence) | Baseline; 15 minutes following last naloxone dose | Participants in the Prevention of Physical Dependence Arm were analyzed. | units on a scale | MEAN |
| SECONDARY | Change in Subjective Opioid Withdrawal Score From Baseline (Prevention of Physical Dependence) | Baseline; 15 minutes following last naloxone dose | Participants in the Prevention of Physical Dependence Arm were analyzed. | units on a scale | MEAN |
| SECONDARY | Beck Depression Inventory Score (BDIS) Change From Baseline (Prevention of Physical Dependence) | 2 study days 1 month apart (at the start of each study visit) | Participants in the Prevention of Physical Dependence Arm were analyzed. | units on a scale | MEAN |
| SECONDARY | Profile of Mood States (POMS) Change in Score From Baseline (Prevention of Physical Dependence) | Baseline; 15 minutes following last naloxone dose | Participants in the Prevention of Physical Dependence Arm were analyzed. | units on a scale | MEAN |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) | Prevention of Opioid Withdrawal | Change in OOWS (Ondansetron) | 3.6 | Standard Deviation 2.2 | units on a scale |
| Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) | Prevention of Opioid Withdrawal | Change in OOWS (Placebo) | 3.6 | Standard Deviation 2.4 | units on a scale |
| Change in Subjective Opioid Withdrawal Score (SOWS) From Baseline (Prevention of Opioid Withdrawal) | Prevention of Opioid Withdrawal | Change in SOWS (Ondansetron) | 12.5 | Standard Deviation 11.2 | units on a scale |
| Change in Subjective Opioid Withdrawal Score (SOWS) From Baseline (Prevention of Opioid Withdrawal) | Prevention of Opioid Withdrawal | Change in SOWS (Placebo) | 12.2 | Standard Deviation 10.7 | units on a scale |
| Beck Depression Inventory Score (BDIS) Change From Baseline (Prevention of Opioid Withdrawal) | Prevention of Opioid Withdrawal | -0.44 | Standard Deviation 3.36 | units on a scale | |
| Profile of Mood States (POMS) Change in Score From Baseline (Prevention of Opioid Withdrawal) | Prevention of Opioid Withdrawal | Change in POMS Score (Ondansetron) | 29.3 | Standard Deviation 31.3 | units on a scale |
| Profile of Mood States (POMS) Change in Score From Baseline (Prevention of Opioid Withdrawal) | Prevention of Opioid Withdrawal | Change in POMS Score (Placebo) | 28.3 | Standard Deviation 37.1 | units on a scale |
| Change in Pain Visual Analog Scale (VAS) From Baseline (Prevention of Opioid Withdrawal) | Prevention of Opioid Withdrawal | -2.68 | Standard Deviation 2.23 | units on a scale | |
| Change in Roland-Morris Disability Index (RMDI) From Baseline (Prevention of Opioid Withdrawal) | Prevention of Opioid Withdrawal | -2.59 | Standard Deviation 4.56 | units on a scale | |
| Change in Objective Opioid Withdrawal Score From Baseline (Prevention of Physical Dependence) | Prevention of Physical Dependence | Change in OOWS (Ondansetron) | 4.5 | Standard Deviation 2.5 | units on a scale |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Prevention of Opioid Withdrawal-Ondansetron | 27 | |
| Overall Study | STARTED | Prevention of Opioid Withdrawal-Placebo | 30 | |
| Overall Study | STARTED | Prevention of Physical Dependence - Ondansetron | 40 | |
| Overall Study | STARTED | Prevention of Physical Dependence - Placebo | 36 | |
| Overall Study | COMPLETED | Prevention of Opioid Withdrawal-Ondansetron | 15 | |
| Overall Study | COMPLETED | Prevention of Opioid Withdrawal-Placebo | 18 | |
| Overall Study | COMPLETED | Prevention of Physical Dependence - Ondansetron | 23 | |
| Overall Study | COMPLETED | Prevention of Physical Dependence - Placebo | 25 | |
| Overall Study | NOT COMPLETED | Prevention of Opioid Withdrawal-Ondansetron | 12 | |
| Overall Study | NOT COMPLETED | Prevention of Opioid Withdrawal-Placebo | 12 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Prevention of Opioid Withdrawal | ||
| Total, all-cause mortality | Prevention of Physical Dependence | ||
| Total, other adverse events | Prevention of Opioid Withdrawal | 0 | 33 |
| Total, other adverse events | Prevention of Physical Dependence | 0 | 48 |
| Total, serious adverse events | Prevention of Opioid Withdrawal | 0 | 33 |
| Total, serious adverse events | Prevention of Physical Dependence | 0 | 48 |
Source ClinicalTrials.gov
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA029078 | 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Phy | CHU, LAWRENCE F | STANFORD UNIVERSITY | NATIONAL INSTITUTE ON DRUG ABUSE | 2011 to 2013 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Prevention of Opioid Withdrawal vs Prevention of Physical Dependence: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01549652
GET https://conductscience.org/api/trials/v1/NCT01549652/results?page=2